209809-20-1

Basic information

• Product Name: Methyl 2-(4-aMino-3-broMophenyl)acetate
• Synonyms: Methyl 2-(4-aMino-3-broMophenyl)acetate;(4-Amino-3-bromo-phenyl)-acetic acid methyl ester
• CAS NO: 209809-20-1
• Molecular Formula: C₉H₁₀BrNO₂
• Molecular Weight: 244.0852
• Mol File: 209809-20-1.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 2-(4-aMino-3-broMophenyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-(4-aMino-3-broMophenyl)acetate(209809-20-1)
• EPA Substance Registry System: Methyl 2-(4-aMino-3-broMophenyl)acetate(209809-20-1)

Safety Data

• Hazardous Substances Data: 209809-20-1(Hazardous Substances Data)

Upstream product

• 66955-75-7 2-(4-amino-3-bromophenyl)acetic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 39552-81-3 methyl p-aminophenylacetate 
• 7439-89-6 iron 
• 185200-33-3 methyl (3-bromo-4-nitrophenyl)acetate 
• 150529-73-0 methyl 2-(3-bromophenyl)acetatee 
• 1878-67-7 3-Bromophenylacetic acid 

Downstream Products

• 317356-78-8 methyl 3-bromo-4-[N'-(2-chlorophenyl)ureido] phenylacetate 
• 317356-81-3 methyl 3-bromo-4-[N'-(2-bromophenyl)ureido] phenylacetate 
• 317356-75-5 methyl 3-bromo-4-[N'-(2-methylphenyl)ureido] phenylacetate 
• 34298-84-5 5-indoleacetic acid 
• 317356-82-4 (3-bromo-4-[N'-(2-bromophenyl)ureido]phenyl)acetic acid 
• 317356-79-9 (3-bromo-4-[N'-(2-chlorophenyl)ureido]phenyl)acetic acid 
• 317356-76-6 (3-bromo-4-[N'-(2-methylphenyl)ureido]phenyl)acetic acid 
• 317356-83-5 C₂₈H₂₆Br₂FN₃O₅ 
• 317356-80-2 C₂₈H₂₆BrClFN₃O₅ 
• 317356-77-7 C₂₉H₂₉BrFN₃O₅ 

Relevant articles and documents

SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides of formula (1) and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists

A series of benzoic acid derivatives was synthesized as VLA-4 antagonists. Introduction of chlorine or bromine into the 3-position on the central benzene of the diphenylurea portion as in lead compound 2 led to improvement in the pharmacokinetic properties. In particular, 12l demonstrated an acceptable plasma clearance and bioavailability in mice and rats as well as dogs (mice, CL = 18.5 ml/min/kg, F = 28 %; rats, CL = 5.2 ml/min/kg, F = 36 %; dogs, CL = 3.6 ml/min/kg, F = 55 %). Additionally, 12l exhibited potent activity with an IC50 value of 0.51 nM and efficacy by oral administration at a dosage of 10 mg/kg in a rat pleurisy model.

Antidiabetic agents

The instant invention is concerned with aryl and heteroaryl oxyacetic acid type compounds which are useful antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and related diseases and for lowering triglyceride levels are also disclosed.